Brimonidine

From Self-sufficiency
Jump to: navigation, search
Brimonidine
260px
Systematic (IUPAC) name
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl) quinoxalin-6-amine
Clinical data
Pregnancy
category
  • B
Routes of
administration
Ocular, 1 gtt
Legal status
Legal status
  • unknown
Pharmacokinetic data
Metabolism liver primarily
Biological half-life 3 hours
Identifiers
CAS Number 59803-98-4
ATC code S01EA05 (WHO)
PubChem CID 2435
IUPHAR/BPS 520
DrugBank APRD00034
Chemical data
Formula C11H10BrN5
Molar mass 292.135 g/mol[[Script error: No such module "String".]]
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Brimonidine (bri-MOE-ni-deen, brand names Alphagan and Alphagan-P) is a drug used to treat open-angle glaucoma or ocular hypertension. Alphagan is also used to induce miosis for people suffering from poor night vision after Lasik or PRK surgery.

It acts via decreasing synthesis of aqueous humor, and increasing the amount that drains from the eye. As a treatment for glaucoma, it is usually given in eyedrop form.

Brimonidine is an α2-adrenergic receptor agonist.

Alpha 2 agonists, through the activation of the Gi GPCR, inhibit the activity of adenylate cyclase. This reduces cAMP and hence aqueous humour production by the ciliary body.

Clinical uses

Brimonidine is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

External links

References

  • Mosby's Drug Guide for Nurses (7th edition; Skidmore) 2007.
es:Brimonidina

it:Brimonidina pl:Brymonidyna